You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
普利製藥(300630.SZ):與中科院高能所簽署共建醫藥創新技術中心合作協議
格隆匯 07-27 16:38

格隆匯7月27日丨普利製藥(300630.SZ)公佈,公司(“甲方”)於近日與中國科學院高能物理研究所(“中科院高能所”或“乙方”)簽署了《共建醫藥創新技術中心合作協議》雙方將優勢互補、互惠共贏以乙方基礎研究的優勢學科和技術領域為依託,結合甲方的技術孵化、放大及科、工、國際化一體,聚焦於硼中子藥物、mRNA 核酸藥物、納米多肽藥物、蛋白藥物以及靶向遞送系統等領域,開發面向重大疾病防治領域的醫藥創新藥物進行戰略合作,成立醫藥創新技術中心,集雙方各自優勢,產、學、研合作於一體,開發面向國家重大疾病防治領域的醫藥創新項目

次合作協議的簽署開啟了普利與中科院高能所合作新的起點,雙方將優勢互補、互惠共贏聚焦於治療系列腫瘤藥物疊加治療手段的組合開發,加速研發項目向產業轉化,打通從基礎科研到轉化研究、臨牀研究的創新藥必經之路,實現藥物上市造福患者合作有利於公司在創新藥市場掌握先機,提升公司創新藥物研發實力,豐富公司研發產品線,增厚產品儲備,進一步提高公司核心競爭力,符合公司發展戰略

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account